On April 21, 2026, Erasca, Inc. (the "Company") narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company's pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no later than mid-May of 2026, from the prior guidance of the first half of 2026. The Company is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors, and the Company's licensor, Guangzhou Joyo Pharmatech Co., Ltd. (Joyo), is evaluating ERAS-0015 in the JYP0015M101 trial in China in patients with advanced solid tumors harboring specific RAS mutations.